Global Alzheimer's disease market to reach almost 13 billion dollars by 2030

The Alzheimers disease market is projected to experience robust growth at a compound annual growth rate of 20 per cent from 22 billion in 2020 to 137 billion in 2030 according to a report on WednesdayThe growth will be particularly seen across the eight major markets such as the US France Germany Italy Spain the UK Japan and ChinaThe expansion is primarily attributed to the introduction of pioneering therapies aimed at addressing the challenges posed by Alzheimers noted a report by GlobalData a leading data and analytics companyThe report Alzheimers Disease EightMarket Drug Forecast and Market Analysis Update reveals that the main driver of growth will be the launch of 23 new pipeline products including novel symptomatic therapies for the treatment of agitation associated with the neurological disorder and the entry of diseasemodifying therapies DMTs to the marketIn 2020 the competitive landscape in Alzheimers disease only offered medications such as acetylcholinesterase inhibitors which are aimed at treating the symptoms of the disease said Philippa Salter Neurology Analyst at GlobalData in a statementThese drugs are modestly effective and primarily off patent thus creating significant opportunity for new entrants into the Alzheimers market she addedA major focus of RampD in the Alzheimers therapeutic space is preventing the accumulation of amyloid beta and formation of amyloid beta plaques in the brainDrug developers have finally begun to see some success with this strategy first with the FDA approval of Biogens antiamyloid beta monoclonal antibody mAb Aduhelm aducanumab in 2021 followed by the FDA approval of EisaiBiogens antiamyloid beta mAb Leqembi lecanemab in January 2023The launch of these products and two other antiamyloid beta mAbs Lillys donanemab and remternetug during the forecast period will be a significant driver of growth within the Alzheimers marketAccording to Salter Leqembi and donanemab have both demonstrated that they can reduce cognitive decline in Phase III clinical trials As such they are expected to become the topselling Alzheimers Adrugs by 2030GlobalData forecasts that Leqembi and donanemab could generate global sales of approximately 35 billion and 20 billion in 2030 respectively across the 8 major marketsWhile the AD market is projected to experience strong growth challenges remainThe rates of diagnosis and treatment are low across all stages of the disease so there is an unmet need for accurate easytouse diagnostic tests and for biomarkers that can be used for patient classification and the assessment of treatment response the report saidAlso Read Research reveals that gardening and cycling may help fight off diabetesThis story has been sourced from a third party syndicated feed agencies Midday accepts no responsibility or liability for its dependability trustworthiness reliability and data of the text Midday managementmiddaycom reserves the sole right to alter delete or remove without notice the content in its absolute discretion for any reason whatsoever